RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)
NCT06404099 is a phase 2 interventional trial sponsored by Duke University. As of 21 Nov 2026, it is completed. It studies Modafinil, Modafinil Placebo, Solriamfetol and Solriamfetol Placebo in Hypersomnia, Long COVID and 1 more condition. The registry lists an enrollment of 361 participants at 1 site in 1 country. The registry lists a start date of 12 Aug 2024 and a primary completion date of 24 Mar 2026.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT06404099 |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | Duke University |
| Enrollment | 361 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Hypersomnia, Long COVID and Long COVID-19 |
| Drugs | Modafinil, Modafinil Placebo, Solriamfetol and Solriamfetol Placebo |
| Start | 12 Aug 2024 |
| Primary completion | 24 Mar 2026 |
| Study completion | 20 Apr 2026 |
| Last update posted | 3 Jun 2026 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Christina Barkauskas, MD
Duke Clinical Research Institute
Study Chair - Susan Redline, MD MPH
Brigham and Women's Hospital
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- All Sites Listed Under Nct06404086
Durham
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT06404099
Each answer restates registry values shown on this page.
What is NCT06404099?
NCT06404099 is a phase 2 interventional trial sponsored by Duke University. It studies Modafinil, Modafinil Placebo, Solriamfetol and Solriamfetol Placebo in Hypersomnia, Long COVID and 1 more condition.
Who leads NCT06404099?
The registry names Christina Barkauskas, MD (study chair, Duke Clinical Research Institute) and Susan Redline, MD MPH (study chair, Brigham and Women's Hospital) as overall officials.
Where does NCT06404099 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT06404099 study?
The registered drug and biological interventions are Modafinil, Modafinil Placebo, Solriamfetol and Solriamfetol Placebo.
When did NCT06404099 end?
The registry lists a primary completion date of 24 Mar 2026 and a study completion date of 20 Apr 2026. The sponsor last updated the record on 3 Jun 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.